Immune Pharmaceuticals Inc.
IMNP
IMNP was delisted on the 25th of July, 2018.
17 hedge funds and large institutions have $949K invested in Immune Pharmaceuticals Inc. in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
21% more funds holding
Funds holding: 14 → 17 (+3)
4% more capital invested
Capital invested by funds: $912K → $949K (+$36.9K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$181K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$80.7K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$29.5K |
| 4 |
Bank of New York Mellon
New York
|
+$17.5K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$13.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$29K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$18.1K |
| 3 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$4.78K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.83K |
| 5 |
Goldman Sachs
New York
|
-$83 |
IMNP Hedge Fund Activity: Q1 2017 in Review
17 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Immune Pharmaceuticals Inc. (IMNP) for Q1 2017, worth a combined $949K — up 4% from $912K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new IMNP positions and 2 closed out — a net gain of 5 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $181K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $29K sold.
- 17 institutional investors held Immune Pharmaceuticals Inc. (IMNP) as of Q1 2017, up from 14 in Q4 2016.
- Funds reported $949K of Immune Pharmaceuticals Inc. stock for Q1 2017, up 4% quarter-over-quarter.
- 7 funds opened new Immune Pharmaceuticals Inc. positions in Q1 2017 and 2 closed out, a net change of +5 holders.
- The largest Immune Pharmaceuticals Inc. buyer in Q1 2017 was Vanguard Group, an estimated $181K added.
- The largest Immune Pharmaceuticals Inc. seller in Q1 2017 was Two Sigma Securities, an estimated $29K sold.
Based on aggregated 13F filings for Q1 2017.